8-K: Syros Pharmaceuticals Repays Debt to Oxford Finance in Full

Syros Pharmaceuticals has fully repaid its debt to Oxford Finance LLC, settling its obligations under the loan and security agreement.

Summary

• Syros Pharmaceuticals, Inc. fully repaid all amounts owed to Oxford Finance LLC under the loan and security agreement on February 28, 2025.
• The company paid a total payoff amount of approximately $6,000,000, consisting of cash and non-cash assets.
• Upon payment, all of Syros' indebtedness and obligations to the lenders were discharged in full.
• Oxford Finance LLC will apply any cash proceeds received from the non-cash assets to the remaining payoff amount.
• If the cash proceeds exceed the remaining payoff amount before a specified date, any remaining non-cash assets will be reassigned to Syros, and the excess amount will be repaid to the company.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has successfully repaid its debt, reducing financial risk. However, the use of non-cash assets in the payoff suggests potential liquidity constraints.

Positives

• The full repayment of debt to Oxford Finance LLC eliminates a significant financial obligation for Syros Pharmaceuticals.
• The agreement allows for the potential return of non-cash assets to Syros if their value exceeds the remaining payoff amount after applying cash proceeds.

Future Outlook

The agreement allows for the potential return of non-cash assets to Syros if their value exceeds the remaining payoff amount after applying cash proceeds.

Industry Context

This announcement reflects a positive step for Syros Pharmaceuticals in managing its financial obligations, which is crucial for biotech companies that often rely on debt financing for research and development.

Stakeholder Impact

• Shareholders may view this as a positive development, reducing financial risk.
• Creditors may see this as a sign of improved financial stability.

Key Dates